OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Dholaria on the Safety and Efficacy of P-BCMA-ALLO1 in R/R Myeloma

February 14th 2025

Dr Dholaria discusses the phase 1 trial of P-BCMA-ALLO1, highlighting high response rates, rapid CAR T-cell expansion, and a favorable safety profile in RRMM.

Dr Ahmed on NKTR-255 With CD19-Directed CAR T-Cell Therapy in R/R LBCL

February 14th 2025

Sairah Ahmed, MD, discusses evaluating NKTR-255 in combination with CD19-directed CAR T-cell therapy in patients with relapsed/refractory large B-cell lymphoma.

Dr Sabari on Considerations for Conducting and Interpreting HER2 Testing in NSCLC

February 14th 2025

Joshua K. Sabari, MD, discusses key considerations when testing for HER2 alterations in non–small cell lung cancer

Dr Goy on Unclear Survival Benefit With Neoadjuvant ADT Plus EBRT in Intermediate-Risk Prostate Cancer

February 14th 2025

Barry W. Goy, MD, discusses 15-year survival outcomes with neoadjuvant androgen deprivation therapy plus EBRT in intermediate-risk prostate cancer.

Dr Saad on the Efficacy of Darolutamide Plus ADT In Low and High Volume mHSPC

February 14th 2025

Fred Saad, CQ, MD, FRCS, FCAHS, discusses the efficacy and safety of darolutamide plus ADT in mHSPC according to disease volume.

Dr Wagar on the Role of Adjuvant Immunotherapy in Endometrial Cancer

February 13th 2025

Matthew Wagar, MD, discusses the use of adjuvant immunotherapy in endometrial cancer and the importance of accurate staging in optimizing outcomes.

Dr Kishtagari on Pelabresib Plus Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis

February 13th 2025

The MANIFEST-2 trial showed that pelabresib/ruxolitinib led to greater spleen volume reduction and improved anemia vs ruxolitinib alone in myelofibrosis

Dr Ahluwalia on the Evolution of Precision Medicine in Oncology

February 13th 2025

Manmeet Singh Ahluwalia, MD, MBA, FASCO, discusses oncology advances that were highlighted at the Miami Cancer Institute Precision Oncology Symposium.

Dr McCann on the Treatment Paradigm for HER2+ Breast Cancer With Brain Metastases

February 13th 2025

Kelly E. McCann, MD, PhD, discusses current and evolving treatment strategies for patients with HER2-positive breast cancer who develop brain metastases.

Dr Sullivan on RP1 Plus Nivolumab in Anti–PD-1–Refractory Melanoma

February 12th 2025

Ryan Sullivan, MD, discusses RP1 plus nivolumab in patients with advanced melanoma who progressed on prior anti–PD-1 therapy.

Dr Somaiah on Ongoing Research With Novel Agents in Sarcomas

February 12th 2025

Neeta Somaiah, MD, discusses ongoing research with novel agents that have emerged and those that could soon emerge in the sarcoma treatment paradigm.

Dr Petrella on Selecting Frontline Therapy in Metastatic Melanoma

February 12th 2025

Teresa Petrella, MD, MHSc, FRCPC, discusses considerations in selecting frontline therapy for patients with metastatic melanoma.

Dr Hamid on the Potential for Cancer Vaccines in Melanoma

February 12th 2025

Omid Hamid, MD, provides insight on the potential role of cancer vaccines in melanoma.

Dr Orloff on Treatment Strategies for Rapidly Progressing Uveal Melanoma

February 11th 2025

Marlana M. Orloff, MD, discusses optimal therapeutic approaches for patients with uveal melanoma that is rapidly progressing.

Dr Faries on Emerging CAR T-Cell and TCR Cell Therapies in Melanoma

February 11th 2025

Mark Faries, MD, discusses how CAR T-cell and TCR cell therapies compare with TIL approaches in melanoma.

Dr Moertel on the FDA Approval of Mirdametinib for NF1-Associated Plexiform Neurofibromas

February 11th 2025

Christopher L. Moertel, MD, discusses the FDA approval of mirdametinib for patients with neurofibromatosis type 1–associated plexiform neurofibromas.

Dr Jabbour on Bleximenib Monotherapy in KMT2A+ or NPM1+ R/R Acute Leukemia

February 11th 2025

Elias Jabbour, MD, discusses data for bleximenib in patients with relapsed/refractory acute leukemia harboring KMT2A rearrangements or NPM1 mutations.

Dr Lang on Real-World Outcomes With the KEYNOTE-522 Regimen in Early-Stage TNBC

February 11th 2025

Julie Lang, MD, discusses real-world outcomes of the neoadjuvant KEYNOTE-522 regimen in patients with early-stage triple-negative breast cancer.

Dr McNall-Knapp on HRQOL Outcomes With Mirdametinib in NF1-PN

February 10th 2025

Rene Y. McNall-Knapp, MD, discusses HRQOL outcomes from the ReNeu trial investigating mirdametinib in patients with NF1-PN.

Dr Livingston on the Addition of Hydroxychloroquine to Gemcitabine/Docetaxel in Osteosarcoma

February 10th 2025

John Andrew Livingston, MD, MS, discusses responses with gemcitabine, docetaxel, and hydroxychloroquine in advanced, metastatic osteosarcoma.